The synthesis and in vitro anticancer activity of dihalogenido(eta6-p-cymene)(3,5,6-bicyclophosphite-alpha-D-glucofuranoside)ruthenium(II) complexes are described. The compounds were characterized by NMR spectroscopy and ESI mass spectrometry, and the molecular structures of dichlorido-, dibromido- and diiodido(eta6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-alpha-D-glucofuranoside)ruthenium(II) were determined by X-ray diffraction analysis. The complexes were shown to undergo aquation of the first halido ligand in aqueous solution, followed by hydrolysis of a P--O bond of the phosphite ligand, and finally formation of dinuclear species. The hydrolysis mechanism was confirmed by DFT calculations. The aquation of the complexes was markedly suppressed in 100 mM NaCl solution, and notably only very slow hydrolysis of the P--O bond was observed. The complexes showed affinity towards albumin and transferrin and monoadduct formation with 9-ethylguanine. In vitro studies revealed that the 3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-alpha-D-glucofuranoside complex is the most cytotoxic compound in human cancer cell lines (IC50 values from 30 to 300 microM depending on the cell line).

Ru(II)-arene complexes with pyrone-derived ligands are rendered active against cancer cells by replacement of the coordinated O,O donor with an S,O donor. The different stabilities of these systems may explain the observed influence of the donor atoms on the anticancer activity in vitro.Metal complexes are playing an important role in the treatment of cancer, and many promising compounds have been developed in recent years. 1-4 Ruthenium complexes have been shown to be among the most promising candidates for new metal-based anticancer drugs. Two of them, KP1019 and NAMI-A, are currently undergoing clinical trials. 2,5 Their low general toxicity might be explained by their modes of action, including protein binding and activation by reduction. [5][6][7] More recently, bioorganometallic chemistry has emerged as a new source of anticancer metallodrugs, with titanocene dichloride being the prototype agent of this compound class. 4,8,9 Furthermore, organometallic Ru(II) compounds that are stabilized in their þ2 oxidation state by coordination of an arene ligand have been investigated for their anticancer properties. These piano-stool complexes have been pioneered by the Dyson and Sadler groups, 10,11 who developed compounds with pta (1,3,5-triaza-7-phoshatricyclo[3.3.1.1]-decane) and en (ethylenediamine) ligands, respectively. 10 For the [(η 6 -arene)Ru II (X)(Y)] complexes, DNA base selectivity strongly depends on the character of the chelating ligand Yexchange of the neutral ethylenediamine by anionic acetylacetonate shifts the affinity from guanine to adenine. 12 In addition to en and pta complexes, maltol-derived mono-and polynuclear ruthenium and osmium complexes have been developed. [13][14][15] The linking of two pyridone moieties opened up new possibilities for tuning the in vitro anticancer activity and lipophilicity, and compounds with interduplex cross-linking capacity were obtained. 14,16-18 In the case of the mononuclear Ru(II) complexes, an increase in cytotoxic activity was achieved by derivatization of the pyrone ring with lipophilic aromatic substituents. 13 In order to study the Ru-ligand interaction and its effect on the in vitro anticancer activity, Ru(II)-cymene complexes (Scheme 1) with pyrones and their corresponding, more lipophilic thiopyrones as chelating agents were prepared. 15,19 Such (thio)pyrone systems have already found application in Scheme 1. Synthesis of the Complexes 2a-d Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. J. Inorg. Biochem. 2006, 100, 891-904. (6) Groessl, M.; Reisner, E.; Hartinger, C. G.; Eichinger, R.; Semenova, O.; Timerbaev, A. R.; Jakupec, M. A.; Arion, V. B.; Keppler, B. K. Melchart, M.; Habtemariam, A.; Sadler, P. J. Chem. Commun. 2005, 4764-4776. (12) Fernandez, R.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Chem. Eur. J. 2004, 10, 5173-5179.(13) Peacock, A. F. A.; Melchart, M.; Deeth, R. J.; Habtemariam, A.; Parsons, S.; Sadler, P. J. Chem. Eur. J. 2007, 13, 2601-2613. (14) Mendoza-Ferri, M. G.; Hartinger, C. G.; Eichinger, R. E.; Stoly...

New hydrazone o-HO-phenylhydrazo-β-diketones (OHADB), R(1)NHN═CR(2)R(3) [R(1) = HO-2-C(6)H(4), R(2) = R(3) = COMe (H(2)L(1), 1), R(2)R(3) = COCH(2)C(Me)(2)CH(2)CO (H(2)L(2), 2), R(2) = COMe, R(3) = COOEt (H(2)L(4), 4); R(1) = HO-2-O(2)N-4-C(6)H(3), R(2)R(3) = COCH(2)C(Me)(2)CH(2)CO (H(2)L(3), 3), R(2) = COMe, R(3) = COOEt (H(2)L(5), 5), R(2)R(3) = COMe (H(2)L(6), 6A)], and their Cu(II) complexes [Cu(2)(CH(3)OH)(2)(μ-L(1))(2)] 7, [Cu(2)(H(2)O)(2)(μ-L(2))(2)] 8, [Cu(H(2)O)(L(3))] 9, [Cu(2)(μ-L(4))(2)](n) 10, [Cu(H(2)O)(L(5))] 11, [Cu(2)(H(2)O)(2)(μ-L(6))(2)] 12A and [Cu(H(2)O)(2)(L(6))] 12B were synthesized and fully characterized, namely, by X-ray analysis (4, 5, 7-12B). Reaction of 6A, Cu(NO(3))(2) and ethylenediamine (en) leads, via Schiff-base condensation, to [Cu{H(2)NCH(2)CH(2)N═C(Me)C(COMe)═NNC(6)H(3)-2-O-4-NO(2)}] (13), and reactions of 12A and 12B with en give the Schiff-base polymer [Cu{H(2)NCH(2)CH(2)N═C(Me)C(COMe)═NNC(6)H(3)-2-O-4-NO(2)}](n) 14. The dependence of the OHADB tautomeric equilibria on temperature, electronic properties of functional groups, and solvent polarity was studied. The OHADB from unsymmetrical β-diketones exist in solution as a mixture of enol-azo and hydrazo tautomeric forms, while in the solid state all the free and coordinated OHADB crystallize in the hydrazo form. The relative stabilities of various tautomers were studied by density functional theory (DFT). 7-14 show catalytic activities for peroxidative oxidation (in MeCN/H(2)O) of cyclohexane to cyclohexanol and cyclohexanone, for selective aerobic oxidation of benzyl alcohols to benzaldehydes in aq. solution, mediated by TEMPO radical, under mild conditions and for the MW-assisted solvent-free synthesis of ketones from secondary alcohols with tert-butylhydroperoxide as oxidant.

Vanadium(IV or V) complexes with N,O- or O,O-ligands, i.e., [VO{N(CH2CH2O)3}], Ca[V(HIDPA)2] (synthetic amavadine), Ca[V(HIDA)2], or [Bu4N]2[V(HIDA)2] [HIDPA, HIDA = basic form of 2,2'-(hydroxyimino)dipropionic or -diacetic acid, respectively], [VO(CF3SO3)2], Ba[VO(nta)(H2O)]2 (nta = nitrilotriacetate), [VO(ada)(H2O)] (ada = N-2-acetamidoiminodiacetate), [VO(Hheida)(H2O)] (Hheida = 2-hydroxyethyliminodiacetate), [VO(bicine)] [bicine = basic form of N,N-bis(2-hydroxyethyl)glycine], and [VO(dipic)(OCH2CH3)] (dipic = pyridine-2,6-dicarboxylate), are catalyst precursors for the efficient single-pot conversion of methane into acetic acid, in trifluoroacetic acid (TFA) under moderate conditions, using peroxodisulfate as oxidant. Effects on the yields and TONs of various factors are reported. TFA acts as a carbonylating agent and CO is an inhibitor for some systems, although for others there is an optimum CO pressure. The most effective catalysts (as amavadine) bear triethanolaminate or (hydroxyimino)dicarboxylates and lead, in a single batch, to CH3COOH yields > 50% (based on CH4) or remarkably high TONs up to 5.6 x 103. The catalyst can remain active upon multiple recycling of its solution. Carboxylation proceeds via free radical mechanisms (CH3* can be trapped by CBrCl3), and theoretical calculations disclose a particularly favorable process involving the sequential formation of CH3*, CH3CO*, and CH3COO* which, upon H-abstraction (from TFA or CH4), yields acetic acid. The CH3COO* radical is formed by oxygenation of CH3CO* by a peroxo-V complex via a V{eta1-OOC(O)CH3} intermediate. Less favorable processes involve the oxidation of CH3CO* by the protonated (hydroperoxo) form of that peroxo-V complex or by peroxodisulfate. The calculations also indicate that (i) peroxodisulfate behaves as a source of sulfate radicals which are methane H-abstractors, as a peroxidative and oxidizing agent for vanadium, and as an oxidizing and coupling agent for CH3CO* and that (ii) TFA is involved in the formation of CH3COOH (by carbonylating CH3*, acting as an H-source to CH3COO*, and enhancing on protonation the oxidizing power of a peroxo-VV complex) and of CF3COOCH3 (minor product in the absence of CO).

For Abstract see ChemInform Abstract in Full Text.

The reaction of vic-dioximes with the organonitrile platinum(IV) complexes trans-[PtCl4(RCN)2] (R = Me, CH2Ph, Ph, vic-dioxime = dimethylglyoxime; R = Me, vic-dioxime = cyclohexa-, cyclohepta-, and cyclooctanedione dioximes) proceeds rapidly under relatively mild conditions and affords products of one-end addition of the dioximes to the nitrile carbon, i.e. [PtC4(NH=C(R)ON=[spacer]=NOH)2] (1-6) (R = Me, CH2Ph, Ph, spacer = C(Me)C-(Me) for dimethylglyoxime; R = Me, spacer = C[C4H8]C, C[C5H10]C, C[C6H12]C for the other dioximes), giving a novel type of metallaligand. All addition compounds were characterized by elemental analyses (C, H, N, C1, Pt), FAB mass spectrometry, and IR and 1H, 13C[1H], and 195Pt NMR spectroscopy. X-ray structure determination of the dimethylformamide bis-solvate [PtCl4(NH=C(Me)ON=C(Me)C(Me)=NOH)2] x 2DMF (la) disclosed its overall trans geometry with the dimethylglyoxime part in anti configuration and the amidine one-end (rather than N,N-bidentate) coordination mode of the N-donor ligands. When a mixture of cis- and trans-[PtC4(MeCN)2] in MeCN was treated with dimethylglyoxime, the formation of, correspondingly, cis- and trans-[PtCl4(NH=C(Me)ON=C(Me)C(Me)=NOH)2] (1) was observed and cis-to-trans isomerization in DMSO-d6 solution was monitored by 1H, 2D [1H,15N] HMQC, and 195Pt NMR spectroscopies. Although performed ab initio calculations give evidence that the trans geometry is the favorable one for the iminoacylated species [PtCl4-(ligand)2], the platinum(IV) complex [PtCl4(NH=C(Me)ON=C[C4Hs]C=NOH)2] (4) was isolated exclusively in cis configuration with the two metallaligand "arms" held together by intramolecular hydrogen bonding between the two peripheral OH groups, as it was proved by single-crystal X-ray diffractometry. The classic substitution products, e.g. [PtC12(N,N-dioximato)2] (12-15), are formed in the addition reaction as only byproducts in minor yield; two of them, [PtCl2(C7H11N2O2)2] (14) and [PtCl2(C8H13N2O2)2] (15), were structurally characterized. Complexes (12-15) were also prepared by reaction of the vic-dioximes with [PtCl4L(Me2SO)] (L = Me2SO, MeCN), but monoximes (Me2C=NOH, [C4H8]C=NOH, [C5H10]C=NOH, PhC(H)=NOH, (OH)C6H4C(H)= NOH) react differently adding to [PtCl4(MeCN)(Me2SO)] to give the corresponding iminoacylated products [PtCl4(NH=C(Me)ON=CRR')(Me2SO)](7-11).

or Ph(NH 2 )] to give the corresponding iminoacylated product [Ph 3 PCH 2 Ph][PtCl 5 {HN᎐ ᎐ C(Et)ON᎐ ᎐ CR 1 R 2 }]. All compounds were characterized by elemental analyses, FAB mass spectrometry, IR and 1 H, 13 C-{ 1 H}, 31 P-{ 1 H} and 195 Pt NMR spectroscopies. A crystal structure determination of [Ph 3 PCH 2 Ph][PtCl 5 {NH᎐ ᎐ C(Et)ON᎐ ᎐ C(C 9 H 16 )}] disclosed amidine one-end rather than the N,N-bidentate co-ordination mode of the N-donor ligand. The iminoacylation by oximes was investigated by ab initio methods (at RHF level using quasi-relativistic pseudopotentials for platinum) for [PtCl 5 (NCMe)] Ϫ which were also applied to the related neutral platinum() [PtCl 4 (NCMe) 2 ] and platinum() [PtCl 2 (NCMe) 2 ] complexes. The calculations included geometry optimization of the starting and final complexes, location of possible transition states for the reaction discussed and intrinsic reaction coordinate calculations for one reaction. The results obtained provided an interpretation, on the basis of kinetic (activation energies) and thermodynamic (reaction energies) effects, for the order of reactivity observed [neutral Pt IV > anionic Pt IV > neutral Pt II ] and indicated that a mechanism based on nucleophilic addition of the protic nucleophile (undeprotonated oxime), to form a transition state with a four-membered NCOH ring, is energetically favoured relative to the alternative one involving prior deprotonation of the oxime, unless base-catalysed conditions are operating. Scheme 1 Reactions of Pt IV -bound organonitriles with oximes and nitrones.

The Schiff bases H3dfmp(L)2 obtained by the condensation of 2,6-diformyl-4-methylphenol and hydrazones [L = isonicotinoylhydrazide (inh), nicotinoylhydrazide (nah) and benzoylhydrazide (bhz)] are prepared and characterized. By reaction of [V(IV)O(acac)2] and the H3dfmp(L)2 in methanol the V(IV)O-complexes [V(IV)O{Hdfmp(inh)2}(H2O)] (1), [V(IV)O{Hdfmp(nah)2}(H2O)] (2) and [V(IV)O{Hdfmp(bhz)2}(H2O)] (3) were obtained. Upon their aerial oxidation in methanol [V(V)O(OMe)(MeOH){Hdfmp(inh)2}] (4), [V(V)O(OMe)(MeOH){Hdfmp(nah)2}] (5) and [V(V)O(OMe)(MeOH){Hdfmp(bhz)2}] (6) were isolated. In the presence of KOH, oxidation of 1-3 results in the formation of [V(V)O2{H2dfmp(inh)2}]n·5H2O (7), K[V(V)O2{Hdfmp(nah)2}] (8) and K[V(V)O2{Hdfmp(bhz)2}] (9). All compounds are characterized in the solid state and in solution, namely by spectroscopic techniques (IR, UV-Vis, EPR, (1)H, (13)C and (51)V NMR), and DFT is also used to calculate the V(IV) hyperfine coupling constants of V(IV)-compounds and (51)V NMR chemical shifts of several V(V)-species and assign them to those formed in solution. Single crystal X-ray analysis of [V(V)O(OMe)(MeOH){Hdfmp(bhz)2}] (6) and [V(V)O2{H2dfmp(inh)2}]n·5H2O (7) confirm the coordination of the ligand in the dianionic (ONO(2-)) enolate tautomeric form, one of the hydrazide moieties remaining non-coordinated. In the case of 7 the free N(pyridine) atom of the inh moiety coordinates to the other vanadium center yielding a polynuclear complex in the solid state. It is also demonstrated that the V(V)O2-complexes are catalyst precursors in the oxidative bromination of styrene by H2O2, therefore acting as functional models of vanadium dependent haloperoxidases. Plausible intermediates involved in the catalytic process are established by UV-Vis, (51)V NMR and DFT studies.